03-13-2019 05:38 AM CET - Advertising, Media Consulting, Marketing Research
Print

Tuberculosis Drugs: Hopes Pinned on Renewed Government Investments in Emerging Economies

Press release from: Coherent Market Insights
Tuberculosis Drugs
Tuberculosis Drugs


Tuberculosis Drugs Market is expected to have a highly positive outlook for the next five years 2018–2026 according to a recently released Tuberculosis Drugs Market research report. The report has been added in his large database by Coherent Market Insights.”
Multidrug-Resistant Tuberculosis (MDR-TB) is highly prevalent worldwide. Around 3% of all new cases diagnosed with TB worldwide have multidrug-resistant tuberculosis and the percentage is more in patients who had already accepted anti-tuberculosis treatment replicating the failure of programs intended to ensure complete cure of patients with tuberculosis. Management of multidrug-resistant tuberculosis is difficult and it requires skilled clinicians at centers with well-equipped laboratory services and DOTS-Plus strategy.

Download PDF Brochure of This Business Research Report @ www.coherentmarketinsights.com/insight/request-pdf/191

Major players involved in global tuberculosis drugs market are
- Pfizer
- Lupin Laboratories
- AstraZeneca
- Cadila Pharmaceuticals
- Novartis AG
- Alkem Laboratories
- Cipla

Prevalence of tuberculosis is high in low-income and emerging economies such as Asia, which includes China, India, Bangladesh, Indonesia, and Pakistan contributing 50% of the global tuberculosis burden. Africa is one of the most tuberculosis infested regions globally and unambiguously the sub-Saharan Africa has the highest rate of tuberculosis incidence, with 83 and 290 patients per 100,000, respectively. Tuberculosis cases occur highly between the age group of 15 to 49 year.

According to World Health Organization (WHO), tuberculosis accounted for burden of US$ 12 billion from low income economies. According to the same source, average work time lost by an individual after getting infected by tuberculosis bacteria is around 3–4 months, which further result in a mean lost potential earnings of 20%–30% of the annual household income and over deaths caused by premature tuberculosis deaths the loss of income is ~15 years Therefore, the global tuberculosis drugs market is expected to witness steady growth over the forecast period.

This report segments the global tuberculosis drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is categorized into first line drugs, Second line drugs and combination drug therapy. Under First line drugs, the market is further segmented into drugs such as Isoninazid, Rifampicin, Ethambutol, Pryazinamide, and Strepromycin. The second line drugs are further segmented into Injectable, Fluoroquinolones, and Bacteriostatic Agents and Others.

For comprehensive understanding of market dynamics, the global tuberculosis drugs market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Get Sample Copy of This Business Research Report @ www.coherentmarketinsights.com/insight/request-sample/191

Detailed Segmentation:
Global Tuberculosis Drugs Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.
News-ID: 1649916 • Views: 195
More releasesMore releases

You can edit or delete your press release here: